Clinical Trial Update: Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daily oral regorafenib in chemotherapy-refractory, metastatic, and locally advanced angiosarcoma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Northwestern University | Conditions: Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-29